Incidence of thrombotic complications in hospitalised and non-hospitalised patients after COVID-19 diagnosis by Tholin, Birgitte et al.
Incidence of thrombotic complications in hospitalised and
non-hospitalised patients after COVID-19 diagnosis
Birgitte Tholin,1
Waleed Ghanima,1,2,3 Gunnar Einvik,2,4
Bernt Aarli,5,6 Eivind Brønstad,7,8
Ole H. Skjønsberg2,9 and
Knut Stavem2,4,10
1Clinic of Internal Medicine, Østfold
Hospital, Gralum, 2Institute of Clinical
Medicine, University of Oslo, 3Department
of Haematology, Oslo University Hospital,
Oslo, 4Department of Pulmonary Medicine,
Akershus University Hospital, Lørenskog,
5Department of Thoracic Medicine,
Haukeland University Hospital,
Haukeland, 6Department of Clinical
Science, University of Bergen, Bergen,
7Thoracic Department, St. Olavs Hospital,
8Department of Circulation and Medical
Imaging, Faculty of Medicine and Health
Sciences, NTNU, Trondheim, 9Department
of Pulmonary Medicine, Oslo University
Hospital Ulleval, Oslo, and 10Health
Services Research Unit, Akershus University
Hospital, Lørenskog, Norway
Received 25 January 2021; accepted for
publication 7 April 2021
Correspondence: Birgitte Tholin, Clinic of




Infection with coronavirus disease-2019 (COVID-19) may predispose for venous
thromboembolism (VTE). There is wide variation in reported incidence rates of
VTE in COVID-19, ranging from 3% to 85%. Therefore, the true incidence of
thrombotic complications in COVID-19 is uncertain. Here we present data on the
incidence of VTE in both hospitalised and non-hospitalised patients from two
ongoing prospective cohort studies. The incidence of VTE after diagnosis of
COVID-19 was 39% [95% confidence interval (CI): 21–72] during hospitalisation,
09% (95% CI: 02–31) in the three months after discharge and 02% (95% CI:
000–125) in non-hospitalised patients, suggesting an incidence rate at the lower
end of that in previous reports.
Keywords: coronavirus disease-2019, venous thromboembolism, anticoagu-
lation, epidemiology, incidence.
Introduction
During the past year, numerous studies have reported on the
incidence and prevalence of venous thromboembolism (VTE)
in coronavirus disease-2019 (COVID-19) patients, with inci-
dence rates varying from 3% to 85%, depending on popula-
tions, settings and assessment methods.1-4 Variations may
also be associated with a lack of a consensus on the indica-
tion, dosage and duration of prophylactic anticoagulation.
The majority of reports are from studies of selected patients
or hospital cohorts using intensive case findings. The infor-
mation on the incidence of VTE after hospital discharge and
among those not needing hospital admission is limited.
This study assessed the incidence of VTE in both hospitalised
and non-hospitalised patients in two ongoing cohort studies in
Norway. Furthermore, we assessed the variation in the use of
prophylactic anticoagulation between five hospitals.
Methods
Participants and data collection
PROLUN (patient-reported outcomes and lung function after
hospitalisation for COVID-19) is an ongoing multicentre
prospective cohort study in six Norwegian hospitals compris-
ing 262 surviving patients hospitalised before June 1, 2020.
Patients with a discharge diagnosis of U07.1 (confirmed
COVID-19 diagnosis), U07.2 (COVID-19, diagnosis uncon-
firmed) or J12.x [viral pneumonia, in combination with posi-
tive Severe Acute Respiratory Syndrome Coronavirus-2
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(SARS-CoV-2) polymerase chain reaction (PCR)] were con-
sidered eligible. Consenting patients were invited to a three-
month follow-up visit.5 At the follow-up, patients were asked
if they had been diagnosed with a VTE during the last
months, which was subsequently verified by medical record
review. Through a re-review of medical records, we also
checked if the patients had been prescribed anticoagulation
for primary thromboprophylaxis at discharge.
PROTROM (patient-reported outcomes and thromboem-
bolism after COVID-19 without hospitalisation) is another
ongoing prospective population-based cohort study assess-
ing non-hospitalised individuals with COVID-19.6 Patients
from the geographical catchment area of two Norwegian
hospitals [Akershus University Hospital (Ahus) and Østfold
Hospital (ØH)] with a positive real-time PCR for SARS-
CoV-2 before June 1, 2020 were invited. Patients admitted
to hospital <22 days after a positive PCR test were
excluded, because we considered the probability to be high
that this hospital stay was COVID-19-related. In total, 458
of 938 eligible subjects (49%) responded to a survey on
average four months after symptom onset; 451 (48%)
responded to items on recent VTE. Self-reported VTE
events were verified by medical record review in each local
hospital.
Statistical analysis
The uncertainty of the incidence rates for VTE was estimated
by calculating 95% confidence intervals using the Wilson
method. For display of anticoagulation practice, we excluded
one hospital, as we only included hospitals with ≥20 patients.
Data were analysed using Stata software version 16.1 (Stata-
Corp, College Station, TX, USA).
Results and discussion
Among the 262 hospitalised patients (PROLUN), the median
(25th to 75th percentile) length of stay was 6 (3–12) days,
and 51 patients (19%) were admitted to the intensive-care
unit (ICU). At admission, the median clinical frailty scale
score was 2 (range: 1–7) and 26/262 (10%) were considered
as at least pre-frail (>3). Only (17%) had severe disease
according to the COVID-19 ordinal scale for clinical
improvement (Table I), i.e. requiring non-invasive ventila-
tion, high-flow oxygen, intubation/mechanical ventilation, or
extracorporeal membrane oxygenation (ECMO; only one
patient had ECMO). A chest computed tomography (CT)
was performed in 39/262 (15%) during the hospital stay. Fif-
teen of 262 patients (57%) had a history of prior VTE.
At the three-month follow-up, 232 responded to items
about VTE; 11/232 (5%) patients reported a VTE during or
after being discharged from the hospital, and ten of these
had the diagnosis confirmed by compression ultrasound or
CT pulmonary angiography, as verified by review of medical
records. Thus, the incidence rate of verified VTE during
hospitalisation for COVID-19 was 39% [95% confidence
interval (CI): 21–72] and 09% (95% CI: 02–31) in the
three months after discharge from the hospital (Table I). The
incidence rate among those admitted to the ICU was 78%
(95% CI: 31–185%).
In non-hospitalised patients (PROTROM), 11/458 patients
(24%) had a history of VTE, and 1/451 (02%, 95% CI: 00–
13%) reported a VTE after COVID-19 that was verified.
In the hospitalised patients, the incidence rate was at the
low end of those previously reported.1,2 All patients being
hospitalised before June 1, 2020, with a positive SARS-CoV-2
PCR were included, although many of these patients were
only moderately affected by COVID-19, as shown by the dis-
tribution of scores on the COVID-19 ordinal scale for clini-
cal improvement. Norwegian hospitals have not been
overwhelmed with COVID-19-related admissions compared
to other countries, and so the population hospitalized may
have milder disease than in countries with high demand for
hospital beds. This might contribute to the low incidence of
VTE for the hospitalised patients presented here. In addition,
we only obtained data from patients who were discharged
alive, which represents a limitation. Two recent meta-analy-
ses reported overall incidence rates of 21% (95% CI: 17–
26%) and 26% (95% CI: 6–66%), range 26–854%, for VTE
in hospitalised COVID-19 patients, but it was emphasized
that the quality of the evidence was low due to heterogeneity
and risk of bias.1,2 These variations in incidence rates in pre-
vious reports may largely be explained by the variations in
sample selection and methods.
In the current study, the rate of chest CT during the
hospital stay of 15% was lower than in some other stud-
ies. For example, a recent study reported rates of chest CT
of 1 042/1 259 (83%).7 Yet, the case fatality rate of hospi-
talised patients in Norway seems similar to that in other
countries. In Norway, as of June 21, 2020, 1 142 patients
had been hospitalised with COVID-19; 929 with the dis-
ease as a primary diagnosis, and 94 hospitalised patients
were reported dead with COVID-19, i.e., a case fatality
rate in hospitals of 82% (95% CI: 68–100) or 101%
(95% CI: 83–122), depending on choice of denominator.8
Liberal use of chest CT or compression ultrasonography of
the lower extremities has been discouraged in Norway due
to both capacity challenges and in the interest of infection
control. This practice could possibly have led to underre-
porting in our setting, and physicians might instead have
administered higher doses of low molecular weight heparin
(LMWH). The incidence of symptomatic VTE following
hospital discharge for COVID-19 has been reported to be
02% within 45 days,9 suggesting that most VTEs occur
during the hospital stay.
The uncertainty associated with the true incidence of VTE
in unselected COVID-19 patients might also have influenced
the use of thromboprophylaxis. In this study, we observed a
wide variation in the practice of prophylactic anticoagulation
with LMWH between the participating hospitals (Table II).
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In Norway, the use of prophylactic anticoagulation was
liberal in the early days of the pandemic due to several case
reports and smaller studies reporting a high incidence of
VTE in COVID-19 patients.10,11 The majority of patients in
PROLUN received ≥ 5 000 iu dalteparin as thromboprophy-
laxis, and in total 66% received anticoagulation, initiated
Table I. Patient characteristics and incidence of VTE in the PROLUN and PROTROM studies.
PROLUN (hospitalised) PROTROM (non-hospitalised)
(n = 262) (n = 458)
Age (years), mean (SD) 586 (142) 496 (153)
Male 151 (58) 202 (44)
Comorbidity
Hypertension 80* (33) 86 (19)
Asthma 51 (19) 52 (11)
Diabetes 22 (8) 16 (3)
COVID-19 ordinal scale for clinical improvement
1–2, ambulatory 0 458 (100)
3, hospitalised, no oxygen therapy 91 (35) 0
4, hospitalised, oxygen by mask or nasal prongs 126 (48) 0
5–7, hospitalised, non-invasive
ventilation, high flow oxygen,
intubation/mechanical ventilation, or ECMO
45 (17) 0
History of VTE 15 (6) 11 (2)
Anticoagulated prior to admission† 19 (7) NA
Anticoagulation initiated in hospital 154 (59) NA
Discharged with thromboprophylaxis‡ 19 (7) NA
Follow-up after 3–4 months 232 (89) NA
Self-reported VTE 11§ (5) 1¶,** (02)
Verified VTE 10 (43, 95% CI: 24–78) 1¶,** (02, 95% CI: 00–13)
VTE during hospital stay 8 (39, 95% CI 21–72) NA
Verified VTE in ICU patients†† 4 (78, 95% CI: 31–185) NA
VTE after discharge 2‡‡ (09, 95% CI 02–31) NA
ECMO, extracorporeal membrane oxygenation; VTE, venous thromboembolism; ICU, intensive care unit; CI, confidence interval; NA, not appli-
cable.
*Self-reported, n = 239.
†Direct oral anticoagulants, warfarin or low molecular weight heparin (LMWH).
‡Primary thrombotic prophylaxis in patients not diagnosed with a VTE, n = 262.
§Deep venous thrombosis, four pulmonary embolism.
¶n = 451.
**Pulmonary embolism.
††Three months after discharge.
‡‡n = 51. Data presented as absolute number (%) unless stated otherwise.
Table II. Dosage and use of prophylactic LMWH* initiated in five participating hospitals, number (%).
Hospital
A B C D E Total
LMWH dose
None 45 (42) 23 (34) 5 (16) 20 (69) 15 (75) 111 (42)
2 500 iu 1 (09) 2 (3) 0 (0) 2 (7) 5 (25) 10 (4)
5 000 iu 40 (37) 29 (43) 20 (65) 5 (7) 0 (0) 95 (36)
>5 000 iu 22 (20) 13 (19) 6 (19) 2 (7) 0 (0) 46 (17)
Sum 108 (100) 67 (100) 31 (100) 29 (100) 20 (100) 255 (100)
Only hospitals with ≥20 patients are presented. LMWH, low molecular weight heparin; iu, international units.
*Dalteparin.
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prior to or during the hospitalisation. Although 5 000 iu dal-
teparin once daily is the standard thromboprophylactic
dosage for immobilisation because of acute illness in Norway,
17% of patients received higher doses, and only 19% of
those receiving prophylactic anticoagulation during hospital-
ization were diagnosed with a VTE. This might have influ-
enced the incidence of VTE in this study, although the
number of VTE events was considered too small to compare
the results between hospitals. It is possible that the variation
might be smaller now, after implementation of more recent
guidelines on anticoagulation during COVID-19 like the
American Society of Hematology suggesting using prophylac-
tic-intensity anticoagulation in patients who do not have sus-
pected or confirmed VTE.12
In other studies, a fair proportion of patients have been
diagnosed with VTE despite prophylactic anticoagulation.7
This can be used as an argument for the use of higher doses
of prophylactic anticoagulation than usual, which seems to
be practiced at several hospitals.
There is little information available on the incidence of
VTE among those not hospitalised for COVID-19, except for
some case reports.13 We found a low incidence rate of VTEs
following COVID-19. This low rate may be explained by a
healthier population with a lesser degree of inflammation,
immobilization and possibly comorbidities, than in hospi-
talised patients. Moreover, the sample in this study was pop-
ulation-based with a 48% response to the item on VTE and
should therefore be reasonably representative of non-hospi-
talised COVID-19 patients. It is possible that patients with
an increased symptom burden (i.e. if they have a VTE)
respond more often than patients without symptoms,
although patients with considerable comorbidity or language
problems may have a lower propensity to respond. Therefore,
responder bias may influence the findings, although it is not
evident in what direction this would work. It was not possi-
ble to assess the incidence rate of VTEs among non-partici-
pants in the survey. There is, however, a possibility that
some patients diagnosed with a VTE within 21 days of hav-
ing a positive COVID-19 test might have been hospitalised
and thereby excluded. One may also speculate that some
patients may have hesitated to seek medical attention due to
the ongoing pandemic. This might contribute to the low
incidence rate in our study.
If the incidence of VTE in non-hospitalised patients is as
low as these results suggest, large-scale data from population-
based studies or studies with record linkage between reg-
istries may provide more accurate data, although verification
of the events may be more difficult.14
Reported incidence rates of VTE in COVID-19 may seem
high; however, it is not clear if the incidence of VTE is
higher in COVID-19 than in other viral or bacterial pneumo-
nias, e.g. community-acquired pneumonia.15 This may easily
be forgotten during the current pandemic.
In conclusion, in this study, we found a low incidence rate
of VTEs compared to previous reports in hospitalised
patients. In a population-based study of non-hospitalised
COVID-19 patients, the incidence rate was considerably
lower (02%). These incidence rates are at the low end of
previous reports. The study also noticed a wide variation in
the practice of prophylactic anticoagulation in the hospi-
talised patients.
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